# Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias

> **NIH NIH R01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2021 · $27,371

## Abstract

Project Summary
This is an application for a Research Supplement to Promote Diversity in Health-Related Research (PA-20-222).
The parent R01 grant associated with this application is entitled “Targeting Lysine Methyltransferases EZH2
and EZH1 for Treating MLL-rearranged Leukemias” supported by NCI (5R01CA218600-04). Julia Velez is the
diversity candidate. She is a US citizen of Hispanic/Latino descent and is currently an PhD student at Icahn
School of Medicine at Mount Sinai, New York. The main goal of this study is to identify and characterize
promising EZH2/1 degraders in MLL-rearranged leukemia cellular models.

## Key facts

- **NIH application ID:** 10282388
- **Project number:** 3R01CA218600-04S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Jian Jin
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $27,371
- **Award type:** 3
- **Project period:** 2017-06-08 → 2022-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10282388

## Citation

> US National Institutes of Health, RePORTER application 10282388, Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias (3R01CA218600-04S1). Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/grant/nih/10282388. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*